Formycon's COVID-19 Drug FYB207 even more efficient against SARS-CoV-2 Mutant B.1.1.7

DGAP-News: Formycon AG / Key word(s): Study/Scientific publication
25.03.2021 / 07:00
The issuer is solely responsible for the content of this announcement.

Press Release // March 25, 2021

Formycon's COVID-19 Drug FYB207 even more efficient against SARS-CoV-2 Mutant B.1.1.7

Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY), together with its academic partners Prof. Dr. Ulrike Protzer, Chair of Virology, and Prof. Dr. Johannes Buchner, Chair of Biotechnology, Technical University of Munich, today announced new results on the in vitro neutralization of SARS-CoV-2 variants by Formycon's COVID-19 drug FYB207. These show that FYB207 is even more efficient against the B.1.1.7 mutant of the virus, which is considered particularly infectious, than against earlier variants.

The study, which builds on previous published data (BioRxiv Preprint: https://doi.org/10.1101/2020.12.06.413443) will be presented today at the "30^th Annual Meeting of the Society for Virology" and is titled "Singular ACE2-IgG4-Fc fusion protein efficiently inhibits SARS-CoV-2 entry". The presentation will be available soon on our website https://www.formycon.com/en/pipeline/fyb207/.

In the current study, a series of SARS-CoV-2 variants with increasing infectivity were tested: (I) SARS-CoV-2-Jan, isolated from a COVID-19 patient from the earliest documented COVID-19 outbreak in Germany in January 2020, which was directly related to the first outbreak in Wuhan, China, (II) SARS-CoV-2-April, which was isolated when the virus first spread massively in Europe in April 2020, and (III) SARS-CoV-2 variant B.1.1.7, which was first detected in the United Kingdom in September 2020, is associated with increased infectivity and mortality, and soon became the predominant SARS-CoV-2 variant in Europe.

The FYB207 concentration required for 50% inhibition in vitro (IC50 value) is in the low nanomolar range and decreased with each variant: (I) 4.7 nM, (II) 1.3 nM, (III) 0.6 nM, clearly showing that the neutralizing activity of FYB207 increased the more infectious and harmful the SARS-CoV-2 variant was. The IC50 values for FYB207 suggest a high neutralizing activity against SARS-CoV-2 B.1.1.7. The in vitro neutralization assay is considered a surrogate for potential therapeutic efficacy in SARS-CoV-2 infected patients.

"Health authorities around the world are increasingly concerned that neutralizing antibodies or vaccines may lose their activity against emerging SARS-CoV-2 mutants. While studies with neutralizing antibodies and sera from vaccinated individuals in vitro have indicated a reduction in neutralizing activity against B.1.1.7 and further SARS-CoV-2 mutants, our new in vitro data show that FYB207 neutralizes SARS-CoV-2 mutant B.1.1.7 even more. These results support our strategy to develop FYB207 as a treatment option for COVID-19 patients, but also to contribute to the preparedness for the outbreak of new coronavirus mutants", says Dr. Carsten Brockmeyer, CEO of Formycon AG.

SARS-CoV-2 and other coronaviruses use the ACE2 protein on the surface of human cells as a portal of entry for respiratory tract infections. Formycon has therefore fused the human ACE2 protein to the constant part of human immunoglobulin G4 (IgG4) using computational structural design, creating a very effective SARS-CoV-2 blocker that completely prevents cell infection in vitro.

Compared to vaccines and therapeutic antibodies, the ACE2-IgG4-Fc fusion protein is maximally protected against escape of the virus by mutation. The risk of infection amplification by vaccines and IgG1 antibodies, described for coronaviruses, is minimized by using the IgG4 portion in the fusion. FYB207 also has inherent enzymatic activity that may provide patients with additional pulmonary and cardiovascular protection. In addition, FYB207 can potentially be used with all coronaviruses that use ACE2 as a portal of entry.

The preclinical activities as well as the preparations for the entry into clinical trials with FYB207 are proceeding according to plan. In addition, Formycon had a successful Scientific Advice Meeting with the Paul-Ehrlich-Institute and has already secured GMP manufacturing capacity for FYB207.

Formycon, together with its academic research partners, is receiving funding from the Bavarian Research Foundation for the initial development steps of this project.

About Formycon:
Formycon is a leading, independent developer of high-quality biopharmaceutical medicines, especially biosimilars. The company focuses on treatments in ophthalmology, immunology and on other key chronic diseases, covering the entire value chain from technical development to the clinical phase III as well as the preparation of dossiers for marketing approval. With its biosimilars, Formycon is making a major contribution towards providing as many patients as possible with access to vital and affordable medicines. Formycon currently has four biosimilars in development. Based on its extensive experience in the development of biopharmaceutical drugs, the company is also working on the development of a COVID-19 fusion protein.

Contact:
Sabrina Müller
Senior Manager Corporate Communications and Investor Relations
Formycon AG
Fraunhoferstr. 15
82152 Martinsried/Planegg/Germany
Phone: +49 (0) 89 - 86 46 67 149
Fax + 49 (0) 89 - 86 46 67 110
Sabrina.Mueller@formycon.com // www.formycon.com

Disclaimer:
This press release may contain forward-looking statements and information which are based on our current expectations and certain assumptions. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, performance of the company, development of the products and the estimates given here. Such known and unknown risks and uncertainties comprise, among others, the research and development, the regulatory approval process, the timing of the actions of regulatory bodies and other governmental authorities, clinical results, changes in laws and regulations, product quality, patient safety, patent litigation, contractual risks and dependencies from third parties. With respect to pipeline products, Formycon AG does not provide any representation, warranties or any other guarantees that the products will receive the necessary regulatory approvals or that they will prove to be commercially exploitable and/or successful. Formycon AG assumes no obligation to update these forward-looking statements or to correct them in case of developments which differ from those anticipated. This document neither constitutes an offer to sell nor a solicitation of an offer to buy or subscribe for securities of Formycon AG. No public offering of securities of Formycon AG will be made nor is a public offering intended. This document and the information contained therein may not be distributed in or into the United States of America, Canada, Australia, Japan or any other jurisdictions, in which such offer or such solicitation would be prohibited. This document does not constitute an offer for the sale of securities in the United States.

25.03.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de